Kamada Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Kamada Ltd. on February 17, 2015, covering the month of February 2015. The filing serves to disclose specific interest rate terms for the company's Series C Debentures.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, or overall liquidity. The only financial metric disclosed is the interest rate for the Series C Debentures:
- Series C Debenture Interest Rate: 1.57864% for the period from December 1, 2014, to February 28, 2015.
- Annualized Interest Rate: 6.31456%.
- Payment Date: March 1, 2015.
- Record Date: February 17, 2015.
- Ex-Date: February 17, 2015.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely announces the specific interest rate applicable to the current quarter for the Series C Debentures.
Guidance, Outlook, and Risks
The document includes a standard cautionary note regarding forward-looking statements. Risks identified include:
- Unexpected results of clinical trials.
- Delays or denial in U.S. FDA or EMA approval processes.
- Additional competition in the Alpha-1 Antitrypsin Deficiency (AATD) market.
- Further regulatory delays.
The company states it has no obligation to update these forward-looking statements except as required by law.
Key Facts for Investor Verification
- Verify the record date of February 17, 2015, to determine eligibility for the upcoming interest payment.
- Confirm the payment date of March 1, 2015, for the Series C Debenture interest.
- Note that the filing contains no operational or financial performance data for the period.